First-in-human trial demonstrates promise of implantable cytokine factories for ovarian cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 30-Oct-2026 10:16 ET (30-Oct-2026 14:16 GMT/UTC)
Immune checkpoint inhibitors are widely used in elderly cancer patients, but data on tumor-specific immune-related adverse events (irAEs) remain limited. A Chinese Medical Journal study analyzed 407 elderly patients with gastrointestinal (GI) tumors or lung cancer. Results showed higher irAE incidence in lung cancer patients, skin toxicity more prevalent in GI tumor patients, and thyroid dysfunction more common in lung cancer patients. This study provides evidence for personalized safety management of immunotherapy in elderly patients.